<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849026</url>
  </required_header>
  <id_info>
    <org_study_id>WID-CLZ18-BE</org_study_id>
    <nct_id>NCT04849026</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18</brief_title>
  <official_title>A Randomized, Open Label, Multiple-dose, 2-way Crossover, Phase I Study to Compare the Safety and Pharmacokinetics Profile of WID-CLZ18 and Clozaril 100 mg Tablet (Clozapine) After Oral Administration in Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Whanin Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Whanin Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is a randomized, open label, multiple-dose, 2-way crossover, phase I&#xD;
      (Bioequivalence) study to compare the safety and pharmacokinetics profile of WID-CLZ18 and&#xD;
      Clozaril 100 mg tablet (Clozapine) after oral administration in schizophrenia patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Maximum blood concentration in steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Area under the concentration-time curve from zero to 12 hours at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Time to maximum blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Terminal elimination half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Accumulation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>Steady-state peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>(Cmax-Cmin)/Cav</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: WID-CLZ18&#xD;
Period 2: Clozaril 100 mg (Clozapine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Clozaril 100 mg (Clozapine)&#xD;
Period 2: WID-CLZ18</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozaril 100 mg (Clozapine)</intervention_name>
    <description>2 Doses/Day for 10 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WID-CLZ18</intervention_name>
    <description>2 Doses/Day for 10 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Males and females adults aged 20 to 65 years&#xD;
&#xD;
          2. Diagnosed as schizophrenia prior to the screening visit&#xD;
&#xD;
          3. On treatment with a stable dose of clozapine 200 mg/day for at least 12 weeks before&#xD;
             the screening visit and taken at 100 mg twice daily during the study period&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have a medical history specified in protocol&#xD;
&#xD;
          2. Subjects with confirmed abnormal laboratory values specified in protocol&#xD;
&#xD;
          3. Subjects who have a medication history or safety risks specified in protocol&#xD;
&#xD;
          4. Subjects who can not comply with requirements of pharmacokinetic sampling as per&#xD;
             protocol&#xD;
&#xD;
          5. Subjects who are expected to have the prohibited concomitant medication therapy during&#xD;
             the study period&#xD;
&#xD;
          6. Pregnant women or breast-feeding women or men and women who has possibility of&#xD;
             pregnancy&#xD;
&#xD;
          7. Subjects who are not suitable for the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo-Hyun Yoon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Naju National Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Beom Kim</last_name>
    <phone>+82 2 405 3148</phone>
    <email>jbkim88@whanin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoo Jin Park</last_name>
    <phone>+82 2 405 3075</phone>
    <email>yoojin.park@whanin.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Whan In Pharm.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Beom Kim</last_name>
      <email>jbkim88@whanin.com</email>
    </contact>
    <investigator>
      <last_name>Bo-Hyun Yoon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

